Exelixis (EXEL)
News
| May 25 | hand-me downs found in the closet $cxz $exel $nanx.pk $rmbs any thoughts? hold or sell? by mondays |
| May 24 | $exel added some at $4.56. by surjs1 |
| May 18 | 6 Highly Shorted Takeover/LBO Targets Being Bought By Hedge Funds |
| May 17 | Exelixis' Management Presents at Bank of America Merrill Lynch 2012 Health Care Confe... |
| May 17 | Biotech-Focused Baker Bros. $3.7B Fund Bought These 3 Big Winners And Sold Others In ... |
| May 17 | @BioRunUp $exel data is so good then why its going down? by surjs1 |
| May 17 | ASCO '12 Abstract Dump: Cancer Stocks in Focus (Update) |
| May 16 | RT @justfurkids ASCO12 "Most significant cancer drug data came from $AVEO $EXEL & phase II studies by $ARRY " http://stks.co/3rgp by russe9 |
| May 16 | ASCO12 "Most significant cancer drug data came from phase III studies by $AVEO $EXEL & phase II studies by $ARRY " http://stks.co/3rgj by justfurkids |
| May 16 | ASCO '12 Abstract Dump: Cancer Stocks in Focus |
Profile
Exchange: NASDAQGS Sector: Healthcare Industry: Biotechnology
Exelixis, Inc. is a biotechnology company committed to developing small molecule therapeutics for the treatment of cancer. The company is focusing its proprietary resources and development efforts exclusively on Cabozantinib, its most advanced solely-owned product candidate, in order to maximize the therapeutic and commercial potential of this compound. Exelixis believes Cabozantinib has the potential to be a high-quality, differentiated pharmaceutical product that can make a meaningful difference in the lives of patients. The company has also established a portfolio of other novel compounds that it believes have the potential to address serious unmet medical needs. It was founded on November 15, 1994 by Stelios B. Papadopoulos and Corey S. Goodman and is headquartered in South San Francisco, California.
1 Year Total Return Performance
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Exelixis is down 60.25% over the last year vs S&P 500 Total Return up 1.18%, Array BioPharma up 32.58%, and Seattle Genetics up 4.25%.
- EXEL Total Returns
- ^SPXTR Total Returns
- ARRY Total Returns
- SGEN Total Returns
Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these EXEL related companies
Pro Strategies Featuring EXEL
Did Exelixis make it into our Pro Portfolio Strategies?
EXEL Charts
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Other EXEL Resources
- Company Website
- Wiki Page
- Investor Relations
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
- Technical Charts Chart.ly
- Trading Ideas Benzinga
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| EXEL | 4.50 | -0.11 | -2.39% | 684.22M |
| EXE | 3.58 | +0.04 | +1.27% | 37.70M |
| EXC | 36.87 | -0.03 | -0.08% | 31.42B |
| EXBD | 38.15 | +0.26 | +0.69% | 1.262B |
| EXAS | 10.31 | +0.07 | +0.68% | 583.88M |
| EXAR | 8.00 | +0.09 | +1.14% | 355.16M |
| EXAM | 10.94 | +0.07 | +0.64% | 370.67M |
| EWZ | 53.27 | +1.13 | +2.17% | |
| EWX | 40.69 | +1.08 | +2.73% | |
| EWV | 39.25 | +0.47 | +1.21% |
